Wyss InstituteInfectious Disease – Wyss Institute https://wyss.stage.a17.io Wyss Institute at Harvard Thu, 30 Jul 2026 21:38:59 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.6 Kwasi Adu-Berchie named 2024 STAT Wunderkind https://wyss.stage.a17.io/news/kwasi-adu-berchie-named-2024-stat-wunderkind/ Wed, 16 Oct 2024 14:11:12 +0000 https://wyss.harvard.edu/?p=41197 The honor is bestowed annually on the next generation of scientific superstars By Lindsay Brownell (BOSTON) – The Wyss Institute is thrilled to announce that Kwasi Adu-Berchie, Ph.D., a member of the Wyss’ Advanced Technology Team working in Immuno-Materials Platform led by Core Faculty member Dave Mooney, Ph.D., has been named a 2024 STAT Wunderkind by STAT News. The Wunderkinds awards are given annually by STAT News to the next generation of scientific superstars who…

Source

]]> https://wyss.stage.a17.io/news/kwasi-adu-berchie-named-2024-stat-wunderkind/ Kwasi Adu-Berchie https://wyss-stage.imgix.net/app/uploads/2022/08/10092956/Kwasi-Adu-Berchie-3.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=4a6a7501c813f36b02821b455fa1d73c"/> DoriNano – Improved DNA Origami Nanodelivery to Fight Cancer and Other Diseases https://wyss.stage.a17.io/media-post/dorinano-improved-dna-origami-nanodelivery-to-fight-cancer-and-other-diseases/ Fri, 04 Oct 2024 18:20:45 +0000 https://wyss.harvard.edu/?post_type=media_post&p=41135 We’re developing DNA Origami nanodelivery, which is transforming nanoparticle industry. Developed at the Dana Farber Cancer Institute and the Wyss Institute at Harvard University, this innovative approach overcomes the challenges of other nanoparticles, offering stability, high drug loading capacity, nano-scale control of cargo spacing, and more – making it a highly customizable solution for…

Source

]]> https://wyss.stage.a17.io/media-post/dorinano-improved-dna-origami-nanodelivery-to-fight-cancer-and-other-diseases/ https://wyss-stage.imgix.net/app/uploads/2024/10/04142026/THUMBNAIL-DoriNano-Improved-DNA-Origami-Nanodelivery-to-Fight-Cancer-and-Other-Diseases_No-Text.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=08966c8c9814bdc45a545eadd20ac7bd"/> Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies https://wyss.stage.a17.io/news/attivare-licenses-wyss-institutes-immune-modulating-biomaterial-technology-to-advance-immunotherapies/ Wed, 02 Oct 2024 13:20:13 +0000 https://wyss.harvard.edu/?p=41088 The startup is leveraging the biomaterial-based technology to develop novel therapies able to program anti-cancer immunity and prevent infectious diseases By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Attivare Therapeutics Inc. announced that Attivare has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS)…

Source

]]> https://wyss.stage.a17.io/news/attivare-licenses-wyss-institutes-immune-modulating-biomaterial-technology-to-advance-immunotherapies/ The OMNIVAX infection vaccine approach incorporates pathogen-derived antigens into an injectable biomaterial scaffold which presents them together with immune cell attracting and activating factors to dendritic immune cells that then go on to orchestrate multi-faceted immune responses against the pathogen in nearby lymph nodes. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2020/05/20143742/MPS-Scaffold-SEM-001-e1590000157764.jpeg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=b22cd283948c2a998b8ada8474c9e03f"/> Eliz Amar Lewis on Using Many Tools to Fight a Sophisticated Disease https://wyss.stage.a17.io/news/humans-of-the-wyss-eliz-amar-lewis-on-using-many-tools-to-fight-a-sophisticated-disease/ Tue, 24 Sep 2024 14:50:19 +0000 https://wyss.harvard.edu/?p=41047 The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. Eliz Amar Lewis has always been fascinated by biology. But when she saw her grandmother bravely battle breast cancer, she was inspired to use her passion to develop a smart and sophisticated…

Source

]]> https://wyss.stage.a17.io/news/humans-of-the-wyss-eliz-amar-lewis-on-using-many-tools-to-fight-a-sophisticated-disease/ Eliz Amar Lewis, Postdoctoral Fellow. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2024/09/23140755/dsRNA-Eliz-Amar-Lewis-07336.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=8f758cb4d1a3a71b4ba9df3c9617f9a3"/> Wyss Institute team selected by DARPA-SHIELD program to develop first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic https://wyss.stage.a17.io/news/wyss-institute-team-selected-by-darpa-shield-program-to-develop-first-of-its-kind-biologically-engineered-broad-spectrum-antimicrobial-therapeutic/ Mon, 16 Sep 2024 13:25:50 +0000 https://wyss.harvard.edu/?p=40989 Easily deployable and fast-acting approach combines pathogen-binding and immune-activating technologies to assemble a living pathogen-targeting machinery in traumatized individuals By Benjamin Boettner (BOSTON) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University received a contract for up to $12M from the Defense Advanced Research Projects Agency (DARPA)’s new SHIELD program. The SHIELD (Synthetic Hemo-technologies to Locate and Disinfect) program aims to develop a prophylactic treatment that can be broadly administered to…

Source

]]> https://wyss.stage.a17.io/news/wyss-institute-team-selected-by-darpa-shield-program-to-develop-first-of-its-kind-biologically-engineered-broad-spectrum-antimicrobial-therapeutic/ This collaborative research team at the Wyss Institute led by Samir Mitragotri (on the far right) and Michael Super (left of Mitragotri) won a DARPA-SHIELD contract to develop a first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic that can be broadly administered to trauma victims without immediate access to health care facilities. Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2024/09/12130928/SM_Darpa-Shield-Team-Photo-02154-copy.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=0b89c99b44febedf253816eadce2e581"/> Starting a fluorescent biosensor revolution https://wyss.stage.a17.io/news/starting-a-fluorescent-biosensor-revolution/ Thu, 05 Sep 2024 09:00:00 +0000 https://wyss.harvard.edu/?p=40904 Molecular biosensors that only light up upon binding their targets open vast possibilities for medical diagnostics, fundamental research, environmental monitoring, and more By Benjamin Boettner (BOSTON) — Biosensors – devices that use biological molecules to detect the presence of a target substance – have enormous potential for detecting disease biomarkers, molecules-in-action in diverse biological processes, or toxins and other harmful substances in the environment. One of the more common types, fluorescent biosensors, consists of a target-binding biomolecule…

Source

]]> https://wyss.stage.a17.io/news/starting-a-fluorescent-biosensor-revolution/ As an “instant COVID-19 diagnostic,” a binding-activated biosensor, developed to bind the Spike protein of the SARS-CoV-2 virus, is able to detect its target within milliseconds as shown by the development of green fluorescence in this sample. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2024/09/03234828/Fluorescent-Biosensor_Squeeze.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=6e0ac9a6202adb965f6d55a4958f4317"/> Wyss Institute Research Collaboration Awarded ARPA-H Agreement to Develop Disease-Agnostic Immunotherapeutic RNA Platform https://wyss.stage.a17.io/news/wyss-institute-research-collaboration-awarded-arpa-h-agreement-to-develop-disease-agnostic-immunotherapeutic-rna-platform/ Mon, 15 Jul 2024 14:55:26 +0000 https://wyss.harvard.edu/?p=40424 Multidisciplinary project aims to advance novel RNA immunotherapeutic in combination with innovative delivery systems to broadly boost anti-tumor and -pathogen immunity in a range of patient settings By Benjamin Boettner With the award for up to $27M from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.

Source

]]> https://wyss.stage.a17.io/news/wyss-institute-research-collaboration-awarded-arpa-h-agreement-to-develop-disease-agnostic-immunotherapeutic-rna-platform/ In an ARPA-H-funded project, Wyss researchers Natalie Artzi and Donald Ingber, along with Kenneth Carlson and William Shih, will develop a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2024/07/12111451/ARPA-H-Group-Shot-Version-2-00612.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=27b0db9e57b8848fff2c9b68ec5be9ff"/> Human cervix modeled in microfluidic organ chip fills key women’s health gap https://wyss.stage.a17.io/news/human-cervix-modeled-in-microfluidic-organ-chip-fills-key-womens-health-gap/ Fri, 31 May 2024 14:55:29 +0000 https://wyss.harvard.edu/?p=40143 Engineered cervix with in vivo-like mucus production, hormone sensitivity, and associated microbiome creates novel testbed for bacterial vaginosis therapeutics and other treatments By Benjamin Boettner (BOSTON) — Bacterial Vaginosis (BV) has been identified as one of the many unmet needs in women’s health and affects more than 25% of reproductive-aged women. It is caused by pathogenic bacteria that push the healthy microbiomes in the female vagina and cervix – the small gatekeeper canal that connects the uteruns and vagina – into a state of imbalance known as dysbiosis.

Source

]]> https://wyss.stage.a17.io/news/human-cervix-modeled-in-microfluidic-organ-chip-fills-key-womens-health-gap/ Wyss researchers have developed a human Cervix-on-a-Chip that models the complex cervix tissue in vitro, and overcomes major limitations of existing animal and <em>in vitro</em> models to enable the study of bacterial vaginosis and development of drugs. Credit: Shutterstock https://wyss-stage.imgix.net/app/uploads/2024/05/30093346/shutterstock_2079694981.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=dfc20f21950dd60f95918a0dfeac8694"/> Innovating Diagnostics to Improve Clinical Care and Patient Outcomes https://wyss.stage.a17.io/media-post/innovating-diagnostics-to-improve-clinical-care-and-patient-outcomes/ Wed, 15 May 2024 17:46:59 +0000 https://wyss.harvard.edu/?post_type=media_post&p=40004 Guest speaker, Sarah-Beth Perullo, shares the immense difficulty she faced in obtaining a diagnosis for her mysterious symptoms. Her story is a sobering reminder of how frequent patient symptoms are dismissed in the medical field. Credit: Wyss Institute at Harvard University…

Source

]]> https://wyss.stage.a17.io/media-post/innovating-diagnostics-to-improve-clinical-care-and-patient-outcomes/ https://wyss-stage.imgix.net/app/uploads/2024/05/15134536/20231120-Wyss-Retreat-2023-016.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=da47e0b1192dc6907efe0b5e085515eb"/> DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy https://wyss.stage.a17.io/technology/dorivac-boosting-antigen-specific-immune-responses-with-dna-origami-based-vaccines/ Wed, 01 May 2024 17:54:19 +0000 https://wyss.harvard.edu/?post_type=technology&p=34229 Serious diseases like cancer and autoimmune conditions require multiple drugs to treat and manage them, but combining drugs is challenging for a number of reasons. The primary problem is toxicity, as the side effects of multiple drugs can compound each other and produce much greater patient suffering than either drug alone – sometimes to the point that the combination is too dangerous to give to a…

Source

]]> https://wyss.stage.a17.io/technology/dorivac-boosting-antigen-specific-immune-responses-with-dna-origami-based-vaccines/ https://wyss-stage.imgix.net/app/uploads/2022/10/19140258/banner-image-DoriVac.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=dbaf3f18886cd1ae65976a0655e8a751"/>